Form 4: MAIA Biotechnology CEO Vlad Vitoc Reports Stock Option Grant

Vlad Vitoc, CEO of MAIA Biotechnology, reports the acquisition of 200,000 stock options.

Summary

• Vlad Vitoc, the CEO of MAIA Biotechnology, Inc., filed a Form 4 on April 30, 2024.
• The report details a transaction where Vitoc acquired 200,000 stock options.
• These options were granted on April 26, 2024, under the company's 2021 Equity Incentive Plan.
• The options have an exercise price of $2.94.
• The options vest over a 4-year period, with 25% vesting on the first anniversary and the remainder vesting monthly over the following 36 months.
• The options expire on April 26, 2034.

Sentiment

Score: 7

Explanation: The document indicates standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management incentives with shareholder value.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.

Key Dates